<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ojrdrt</journal-id><journal-title-group><journal-title xml:lang="ru">Онкологический журнал: лучевая диагностика, лучевая терапия</journal-title><trans-title-group xml:lang="en"><trans-title>Journal of oncology: diagnostic radiology and radiotherapy</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2587-7593</issn><issn pub-type="epub">2713-167X</issn><publisher><publisher-name>НЕКОММЕРЧЕСКОЕ ПАРТНЕРСТВО «ОБЩЕСТВО ИНТЕРВЕНЦИОННЫХ ОНКОРАДИОЛОГОВ»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.37174/2587-7593-2023-6-4-62-67</article-id><article-id custom-type="elpub" pub-id-type="custom">ojrdrt-330</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ИНТЕРВЕНЦИОННАЯ РАДИОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>INTERVENTIONAL RADIOLOGY</subject></subj-group></article-categories><title-group><article-title>Артериальная химиоинфузия при распространенном гепатоцеллюлярном раке. Обзор литературы</article-title><trans-title-group xml:lang="en"><trans-title>Arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma. Review of the Literature</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9190-116X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Таразов</surname><given-names>П. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Tarazov</surname><given-names>P. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Павел Гадельгараевич Таразов, г. н. с., д. м. н., профессор, заслуженный деятель науки РФ</p><p>197758</p><p>ул. Ленинградская, 70</p><p>Песочный</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>197758</p><p>70, Leningradskaya str.</p><p>Pesochny</p><p>Saint Petersburg</p></bio><email xlink:type="simple">tarazovp@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Российский научный центр радиологии и хирургических технологий им. ак. А.М. Гранова Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>A.M. Granov Russian Research Center of Radiology and Surgical Technologies</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>16</day><month>12</month><year>2023</year></pub-date><volume>6</volume><issue>4</issue><fpage>62</fpage><lpage>67</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Таразов П.Г., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Таразов П.Г.</copyright-holder><copyright-holder xml:lang="en">Tarazov P.G.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.oncoradjournal.ru/jour/article/view/330">https://www.oncoradjournal.ru/jour/article/view/330</self-uri><abstract><p>   Представлен анализ источников литературы по внутриартериальной химиоинфузии при распространенном гепатоцеллюлярном раке. Сделано заключение, что этот метод лечения безопасен и эффективен при новообразованиях большого объема, а также осложненных опухолевым тромбозом воротной вены, когда другие технологии интервенционной радиологии (химиоэмболизация, радиоэмболизация) противопоказаны или малоэффективны. Полученные результаты послужили основанием для включения артериальной химиоинфузии в Южно-Азиатские практические рекомендации по лечению распространенного ГЦР. В рекомендациях США и Европейских стран, включая Россию, упоминания о ней отсутствуют. Учитывая тот факт, что химиоинфузия является относительно недорогой и технически несложной методикой, представляется актуальным исследование ее применимости, в том числе как этапа комбинированного лечения, у неазиатских, в том числе отечественных, пациентов с распространенным ГЦР.</p></abstract><trans-abstract xml:lang="en"><p>   This review summarizes the literature data about hepatic artery infusion chemotherapy in the treatment of advanced hepatocellular carcinoma. This method is safe and effective in tumors of very large volume and also in cases of portal vein tumor thrombosis when other interventional technologies (chemoembolization, radioembolization) are contraindicated or ineffective. Good results are the reasons for inclusion hepatic artery infusion chemotherapy in South-Asia clinical recommendations for the treatment of advanced hepatocellular carcinoma, but this method fails to attend in USA and European guidelines. Arterial infusion chemotherapy looks like non-expensive and technically simple procedure. It’s use in American and European patients including Russiais topical.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>артериальная химиоинфузия</kwd><kwd>гепатоцеллюлярный рак</kwd><kwd>стадия BCLC «C»</kwd><kwd>тромбоз воротной вены</kwd><kwd>интервенционная радиология</kwd></kwd-group><kwd-group xml:lang="en"><kwd>hepatic artery infusion chemotherapy</kwd><kwd>hepatocellular carcinoma</kwd><kwd>stage BCLC “C”</kwd><kwd>portal vein thrombosis</kwd><kwd>interventional radiology</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование проведено без спонсорской поддержки</funding-statement><funding-statement xml:lang="en">The study had no sponsorship</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Reig M, Forner A, Rimola J, et al. BCLC strategy for prognostic prediction and treatment recommendation: The 2022 update J Hepatol. 2022;76(3):681-93. DOI: 10.1016/j.jhep.2021.11.018.</mixed-citation><mixed-citation xml:lang="en">Reig M, Forner A, Rimola J, et al. BCLC strategy for prognostic prediction and treatment recommendation: The 2022 update J Hepatol. 2022;76(3):681-93. DOI: 10.1016/j.jhep.2021.11.018.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Бредер ВВ, Лактионов КП. Гепатоцеллюлярный рак промежуточной стадии BCLC B — официальные рекомендации, как стратегия базисного лечения и точка отсчета в оценке эффективности новых подходов. Злокачественные опухоли. 2016;(4):29-35. URL: https://www.malignanttumors.org/jour/article/view/282</mixed-citation><mixed-citation xml:lang="en">Breder VV, Laktionov KP. Hepatocellular carcinoma of intermediate stage BCLC B – official recommendations as a strategy of basic treatment and point of counting out in evaluation of efficacy of new approaches. Malignant Tumors. 2016;(4):29-35. URL: https://www.malignanttumors.org/jour/article/view/282</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Бредер ВВ, Балахнин ПВ, Виршке ЭР и др. Практические рекомендации по лекарственному лечению больных гепатоцеллюлярным раком : практические рекомендации RUSSCO #3S2, 202025 Злокачественные опухоли. 2020;10(3s2-1):450-69 DOI: 10.18027/2224-5057-2020-10-3s2-25.</mixed-citation><mixed-citation xml:lang="en">Breder VV, Balachnin PV, Virshke ER, et al. Practical recommendations for medical treatment of patients with hepatocellular carcinoma: Practical recommendations RUSSCO #3S2. 202025 Malignant Tumors. 2020;10 (3s2-1):450-69 DOI: 10.18027/2224-5057-2020-10-3s2-25. (in Russian)</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Cerrito L, Annicchiarico BE, Iezzi R, et al. Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers (review). World J Gastroenterol. 2019;25(31):4360-82. DOI: 10.3748/wjg.v25.i31.4360.</mixed-citation><mixed-citation xml:lang="en">Cerrito L, Annicchiarico BE, Iezzi R, et al. Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers (review). World J Gastroenterol. 2019;25(31):4360-82. DOI: 10.3748/wjg.v25.i31.4360.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Krieg S, Essing T, Krieg A, et al. Recent trends and in-hospital mortality of transarterial chemoembolization (TACE) in Germany:A systematic analysis of hospital discharge data between. 2010 and. 2019. Cancers. 2022;14(9):2088. DOI: 10.3390/cancers14092088.</mixed-citation><mixed-citation xml:lang="en">Krieg S, Essing T, Krieg A, et al. Recent trends and in-hospital mortality of transarterial chemoembolization (TACE) in Germany:A systematic analysis of hospital discharge data between. 2010 and. 2019. Cancers. 2022;14(9):2088. DOI: 10.3390/cancers14092088.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Таразов ПГ, Поликарпов АА, Иванова АА Артериальная радиоэмболизация злокачественных опухолей печени стеклянными микросферами иттрия-90: первый опыт / Диагностическая и интервенционная радиология. 2014;8(4):59-66. URL: https://cyberleninka.ru/article/n/arterialnaya-radioembolizatsiya-zlokachestvennyh-opuholey-pecheni-mikrosferami-ittriya-90</mixed-citation><mixed-citation xml:lang="en">Tarazov PG, Polikarpov AA, Ivanova AA. Arterial radioembolization of liver malignancies by glass microspheres of ittrium-90: First experience Diagnostic and Interventional Radiology. 2014;8(4):59-66. URL: https://cyberleninka.ru/article/n/arterialnaya-radioembolizatsiya-zlokachestvennyh-opuholey-pecheni-mikrosferami-ittriya-90 (In Russian)].</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Каприн АД, Иванов СА, Кучеров ВВ и др. Радиоэмболизация печени:исторические очерки и первые отечественные результаты Онкология (журнал им. П.А. Герцена). 2021;10(5):5-12. DOI: 10.17116/onkolog2021100515</mixed-citation><mixed-citation xml:lang="en">Kaprin AD, Ivanov SA, Kucherov VV, et al. Radioembolization of the liver: Historical notes and first domestic results. Onkology (PA Gertzen Journal). 2021;10(5):5-12 (In Russian)</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Alsultan AA, Braat AJAT, Smits MLJ, et al. Current status and future direction of hepatic radioembolization (review)/Clin Oncol. 2021;33(2):106-16. DOI: 10.1016/j.clon.2020.12.003.</mixed-citation><mixed-citation xml:lang="en">Alsultan AA, Braat AJAT, Smits MLJ, et al. Current status and future direction of hepatic radioembolization (review)/Clin Oncol. 2021;33(2):106-16. DOI: 10.1016/j.clon.2020.12.003.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Frantz S, Matsuoka L, Vaheesan K, et al. Multicenter evaluation of survival and toxicities of hepatocellular carcinoma following radioembolization:Analysis of the RESIN registry. J Vasc Interv Radiol. 2021;32(6):845-52. DOI: 10.1016/j.jvir.2021.03.535.</mixed-citation><mixed-citation xml:lang="en">Frantz S, Matsuoka L, Vaheesan K, et al. Multicenter evaluation of survival and toxicities of hepatocellular carcinoma following radioembolization:Analysis of the RESIN registry. J Vasc Interv Radiol. 2021;32(6):845-52. DOI: 10.1016/j.jvir.2021.03.535.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Kwee SA, Wong LL, Sato MM, et al. Transarterial radioembolization for hepatocellular carcinoma with major vascular invasion: A nationwide propensity score-matched analysis with target trial emulation J Vasc Interv Radiol. 2021;32(9):1258-66 E6. URL: https://www.jvir.org/article/S1051-0443(21)01210-0/pdf.</mixed-citation><mixed-citation xml:lang="en">Kwee SA, Wong LL, Sato MM, et al. Transarterial radioembolization for hepatocellular carcinoma with major vascular invasion: A nationwide propensity score-matched analysis with target trial emulation J Vasc Interv Radiol. 2021;32(9):1258-66 E6. URL: https://www.jvir.org/article/S1051-0443(21)01210-0/pdf.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Ahmed S, Gordon L, Dueck D-A, et al. Current status of systemic therapy in hepatocellular cancer (review). Dig Liver Dis. 2021;53(4):397-402.</mixed-citation><mixed-citation xml:lang="en">Ahmed S, Gordon L, Dueck D-A, et al. Current status of systemic therapy in hepatocellular cancer (review). Dig Liver Dis. 2021;53(4):397-402.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Yacoub JH, Mauro D, Moon A, et al. Therapies of hepatocellular carcinoma: Overview, clinical indications, and comparative outcome evaluation Part two: Noncurative intention. Abdom Radiol. 2021;46(8):3540-8. DOI: 10.1007/s00261-021-03074-z.</mixed-citation><mixed-citation xml:lang="en">Yacoub JH, Mauro D, Moon A, et al. Therapies of hepatocellular carcinoma: Overview, clinical indications, and comparative outcome evaluation Part two: Noncurative intention. Abdom Radiol. 2021;46(8):3540-8. DOI: 10.1007/s00261-021-03074-z.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Kang H, Lee HW Current role of systemic therapy in transarterial chemotherapy refractory hepatocellular carcinoma patients (review). Int J Gastrointest Interv. 2021;10(4):183-8. URL: https://www.ijgii.org/journal/view.html?volume=10&amp;number=4&amp;spage=183.</mixed-citation><mixed-citation xml:lang="en">Kang H, Lee HW Current role of systemic therapy in transarterial chemotherapy refractory hepatocellular carcinoma patients (review). Int J Gastrointest Interv. 2021;10(4):183-8. URL: https://www.ijgii.org/journal/view.html?volume=10&amp;number=4&amp;spage=183.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Kudo M. New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma (review). Int J Clin Oncol. 2022;27(7):1110-9. DOI: 10.1007/s10147-022-02166-0.</mixed-citation><mixed-citation xml:lang="en">Kudo M. New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma (review). Int J Clin Oncol. 2022;27(7):1110-9. DOI: 10.1007/s10147-022-02166-0.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Lee S, Kang JH, Kim DY, et al. Prognostic factors of sorafenib therapy in hepatocellular carcinoma patients with failure of transcatheter embolization. Hepatology Int. 2017;11(3):291-9. DOI: 10.1007/s12072-017-9792-3.</mixed-citation><mixed-citation xml:lang="en">Lee S, Kang JH, Kim DY, et al. Prognostic factors of sorafenib therapy in hepatocellular carcinoma patients with failure of transcatheter embolization. Hepatology Int. 2017;11(3):291-9. DOI: 10.1007/s12072-017-9792-3.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Song MJ Hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma. World J Gastroenterol. 2015;21(13):3843-9. DOI: 10.3748/wjg.v21.i13.3843.</mixed-citation><mixed-citation xml:lang="en">Song MJ Hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma. World J Gastroenterol. 2015;21(13):3843-9. DOI: 10.3748/wjg.v21.i13.3843.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Kim B, Won JH, Kim J, et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: Radiologic and clinical factors predictive of survival. Am J Roentgenol. 2021;216(6):1566-72. DOI: 10.2214/AJR.20.23213.</mixed-citation><mixed-citation xml:lang="en">Kim B, Won JH, Kim J, et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: Radiologic and clinical factors predictive of survival. Am J Roentgenol. 2021;216(6):1566-72. DOI: 10.2214/AJR.20.23213.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Nouso K, Miyahara K, Uchida D, et al. Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan. Br J Cancer. 2013;109(7):1904-7. DOI: 10.1038/bjc.2013.542.</mixed-citation><mixed-citation xml:lang="en">Nouso K, Miyahara K, Uchida D, et al. Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan. Br J Cancer. 2013;109(7):1904-7. DOI: 10.1038/bjc.2013.542.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Zaizen Y, Nakano N, Fukumori K, et al. Hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for intrahepatic advanced hepatocellular carcinoma: A propensity score-matched analysis. Cancers. 2021;13(21):5282. DOI: 10.3390/cancers13215282.</mixed-citation><mixed-citation xml:lang="en">Zaizen Y, Nakano N, Fukumori K, et al. Hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for intrahepatic advanced hepatocellular carcinoma: A propensity score-matched analysis. Cancers. 2021;13(21):5282. DOI: 10.3390/cancers13215282.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Chen S, Yuan B, Yu W, et al. Comparison of arterial infusion chemotherapy and chemoembolization for locally advanced hepatocellular carcinoma: A multicenter retrospective study. J Gastrointest, Surg. 2022;26(11):2292-300. DOI: 10.1007/s11605-022-05421-x.</mixed-citation><mixed-citation xml:lang="en">Chen S, Yuan B, Yu W, et al. Comparison of arterial infusion chemotherapy and chemoembolization for locally advanced hepatocellular carcinoma: A multicenter retrospective study. J Gastrointest, Surg. 2022;26(11):2292-300. DOI: 10.1007/s11605-022-05421-x.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Li S, Lyu N, Han X, et al. Hepatic artery infusion chemotherapy using fluorouracil, leucovorin, and oxaliplatin versus transarterial chemoembolization as initial treatment for locally advanced hepatocellular carcinoma: A propensity score-matching analysis. J Vasc Interv Radiol. 2021;32(9):1267-76. DOI: 10.1016/j.jvir.2021.06.008.</mixed-citation><mixed-citation xml:lang="en">Li S, Lyu N, Han X, et al. Hepatic artery infusion chemotherapy using fluorouracil, leucovorin, and oxaliplatin versus transarterial chemoembolization as initial treatment for locally advanced hepatocellular carcinoma: A propensity score-matching analysis. J Vasc Interv Radiol. 2021;32(9):1267-76. DOI: 10.1016/j.jvir.2021.06.008.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Li S, Mei J, Wang Q, et al. Transarterial infusion chemotherapy with FOLFOX for advanced hepatocellular carcinoma: A multi-center propensity score matched analysis of real-world practice. Hepatobilary Surg Nutr. 2021;10(5):631-45. DOI: 10.21037/hbsn.2020.03.14.</mixed-citation><mixed-citation xml:lang="en">Li S, Mei J, Wang Q, et al. Transarterial infusion chemotherapy with FOLFOX for advanced hepatocellular carcinoma: A multi-center propensity score matched analysis of real-world practice. Hepatobilary Surg Nutr. 2021;10(5):631-45. DOI: 10.21037/hbsn.2020.03.14.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Li Q-J, He M-K, Chen H-W, et al. Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: A randomized phase III trial. J Clin Oncol. 2022;40(2):150-60. DOI: 10.1200/JCO.21.00608.</mixed-citation><mixed-citation xml:lang="en">Li Q-J, He M-K, Chen H-W, et al. Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: A randomized phase III trial. J Clin Oncol. 2022;40(2):150-60. DOI: 10.1200/JCO.21.00608.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Salem R Hepatic arterial infusion chemotherapy for large hepatocellular carcinoma: Ready for prime time? (Editorial). J Clin Oncol. 2022;40(2):118-9. URL: https://www.scholars.northwestern.edu/en/publications/hepatic-arterial-infusion-chemotherapy-for-large-hepatocellular-c.</mixed-citation><mixed-citation xml:lang="en">Salem R Hepatic arterial infusion chemotherapy for large hepatocellular carcinoma: Ready for prime time? (Editorial). J Clin Oncol. 2022;40(2):118-9. URL: https://www.scholars.northwestern.edu/en/publications/hepatic-arterial-infusion-chemotherapy-for-large-hepatocellular-c.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Ando E, Tanaka M, Yamashita F, et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: Analysis of 48 cases. Cancer. 2002;95(3):588-95. DOI: 10.1002/cncr.10694.</mixed-citation><mixed-citation xml:lang="en">Ando E, Tanaka M, Yamashita F, et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: Analysis of 48 cases. Cancer. 2002;95(3):588-95. DOI: 10.1002/cncr.10694.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Ikeda M, Okusaka T, Furuse J, et al. A multi-institutional phase II trial of hepatic arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Cancer Chemother Pharmacol. 2013;72(2):463-70. DOI: 10.1007/s00280-013-2222-x.</mixed-citation><mixed-citation xml:lang="en">Ikeda M, Okusaka T, Furuse J, et al. A multi-institutional phase II trial of hepatic arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Cancer Chemother Pharmacol. 2013;72(2):463-70. DOI: 10.1007/s00280-013-2222-x.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Liu M, Shi J, Mou T, et al. Systematic review of hepatic arterial infusion chemotherapy versus sorafenib in patients with hepatocellular carcinoma with portal vein tumor thrombosis. J Gastroenterol Hepatol. 2020;35(8):1277-87. DOI: 10.1111/jgh.15010.</mixed-citation><mixed-citation xml:lang="en">Liu M, Shi J, Mou T, et al. Systematic review of hepatic arterial infusion chemotherapy versus sorafenib in patients with hepatocellular carcinoma with portal vein tumor thrombosis. J Gastroenterol Hepatol. 2020;35(8):1277-87. DOI: 10.1111/jgh.15010.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Hu J, Bao Q, Cao G, et al. Hepatic arterial infusion chemotherapy using oxaliplatin plus 5-fluorouracil versus transarterial chemoembolization/embolization for the treatment of advanced hepatocellular carcinoma with major portal vein tumor thrombosis. Cardiovasc Intervent Radiol. 2020;43(7):996-1005. DOI: 10.1007/s00270-019-02406-3.</mixed-citation><mixed-citation xml:lang="en">Hu J, Bao Q, Cao G, et al. Hepatic arterial infusion chemotherapy using oxaliplatin plus 5-fluorouracil versus transarterial chemoembolization/embolization for the treatment of advanced hepatocellular carcinoma with major portal vein tumor thrombosis. Cardiovasc Intervent Radiol. 2020;43(7):996-1005. DOI: 10.1007/s00270-019-02406-3.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Kosaka Y, Kimura T, Kawaoka T, et al. Hepatic arterial infusion chemotherapy combined with radiation therapy for advanced hepatocellular carcinoma with tumor thrombus of the main trunk or bilobar of the portal vein. Liver Cancer. 2021;10(2):151-60. DOI: 10.1159/000513706.</mixed-citation><mixed-citation xml:lang="en">Kosaka Y, Kimura T, Kawaoka T, et al. Hepatic arterial infusion chemotherapy combined with radiation therapy for advanced hepatocellular carcinoma with tumor thrombus of the main trunk or bilobar of the portal vein. Liver Cancer. 2021;10(2):151-60. DOI: 10.1159/000513706.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Eun JR, Lee HJ, Moon HJ, et al. Hepatic arterial infusion chemotherapy using high-dose 5-fluorouracil and cisplatin with or without interferon-alpha for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombus. Scand J Gastroenterol. 2009;44(12):1477-86. DOI: 10.3109/00365520903367262.</mixed-citation><mixed-citation xml:lang="en">Eun JR, Lee HJ, Moon HJ, et al. Hepatic arterial infusion chemotherapy using high-dose 5-fluorouracil and cisplatin with or without interferon-alpha for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombus. Scand J Gastroenterol. 2009;44(12):1477-86. DOI: 10.3109/00365520903367262.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Kasai K, Ushio A, Kasai Y, et al. Therapeutic efficacy of combination therapy with intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma with portal venous invasion. Cancer. 2012;118(13):3302-10. DOI: 10.1002/cncr.26648.</mixed-citation><mixed-citation xml:lang="en">Kasai K, Ushio A, Kasai Y, et al. Therapeutic efficacy of combination therapy with intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma with portal venous invasion. Cancer. 2012;118(13):3302-10. DOI: 10.1002/cncr.26648.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Wu J, Huang W-J, Wang H-Y, et al. Arterial infusion of 5-fluorouracil combined with subcutaneous injection of pegylated interferon alpha-2b in treating unresectable hepatocellular carcinoma with portal vein tumor thrombus. Med Oncol. 2015;32(3):65. DOI: 10.1007/s12032-015-0491-4.</mixed-citation><mixed-citation xml:lang="en">Wu J, Huang W-J, Wang H-Y, et al. Arterial infusion of 5-fluorouracil combined with subcutaneous injection of pegylated interferon alpha-2b in treating unresectable hepatocellular carcinoma with portal vein tumor thrombus. Med Oncol. 2015;32(3):65. DOI: 10.1007/s12032-015-0491-4.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Wu J-C, Hong T-C, Wu H-T, et al. Hepatic arterial infusion chemotherapy and immune chekpoint inhibitors, alone or in combination, in advanced hepatocellular carcinoma with macrovascular invasion: A single-centre experience in Taiwan. J Gastrointest Oncol. 2023;14(2):849-62. DOI: 10.21037/jgo-22-858.</mixed-citation><mixed-citation xml:lang="en">Wu J-C, Hong T-C, Wu H-T, et al. Hepatic arterial infusion chemotherapy and immune chekpoint inhibitors, alone or in combination, in advanced hepatocellular carcinoma with macrovascular invasion: A single-centre experience in Taiwan. J Gastrointest Oncol. 2023;14(2):849-62. DOI: 10.21037/jgo-22-858.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Fu Y, Peng W, Zhang W, et al. Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis. J Gastroenterol. 2023;58(4):413-24. DOI: 10.1007/s00535-023-01976-x.</mixed-citation><mixed-citation xml:lang="en">Fu Y, Peng W, Zhang W, et al. Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis. J Gastroenterol. 2023;58(4):413-24. DOI: 10.1007/s00535-023-01976-x.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Chen L-T, Martinelli E, Cheng A-L, et al. Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: A TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Ann Oncol. 2020;31(3):334-51. DOI: 10.1016/j.annonc.2019.12.001.</mixed-citation><mixed-citation xml:lang="en">Chen L-T, Martinelli E, Cheng A-L, et al. Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: A TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Ann Oncol. 2020;31(3):334-51. DOI: 10.1016/j.annonc.2019.12.001.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou J, Sun H, Wang Z, et al. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 edition). Liver Cancer. 2020;9(6):682-720. DOI: 10.1159/000509424.</mixed-citation><mixed-citation xml:lang="en">Zhou J, Sun H, Wang Z, et al. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 edition). Liver Cancer. 2020;9(6):682-720. DOI: 10.1159/000509424.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Ge N, Wang H, He C, et al. Optimal interventional treatment for liver cancer: HAIC, TACE or iTACE? (review). J Intervent Med. 2023;6(2):59-63. DOI: 10.1016/j.jimed.2023.03.001.</mixed-citation><mixed-citation xml:lang="en">Ge N, Wang H, He C, et al. Optimal interventional treatment for liver cancer: HAIC, TACE or iTACE? (review). J Intervent Med. 2023;6(2):59-63. DOI: 10.1016/j.jimed.2023.03.001.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Интервенционная радиология в онкологии: Национальное руководство : в 3-х томах. Под ред. БИ Долгушина. М:. 2022. 783 с. ISBN 978-5-88429-265-9.</mixed-citation><mixed-citation xml:lang="en">Interventional radiology in oncology: National guidelines : in 3 volumes. Ed. BI Dolgushina. M:. 2022. 783 p. ISBN 978-5-88429-265-9. (In Russian)</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
